Tags

Type your tag names separated by a space and hit enter

Efficacy of fleroxacin versus amoxicillin in acute exacerbations of chronic bronchitis.
Am J Med. 1993 Mar 22; 94(3A):131S-135S.AJ

Abstract

In a multicenter study the efficacy and safety of oral fleroxacin at 400 mg once a day and amoxicillin at 500 mg three times daily for 7 days were compared for the treatment of patients with acute bacterial exacerbations of chronic bronchitis due to drug-susceptible bacteria. A total of 194 patients were enrolled, 102 in the fleroxacin group and 92 in the amoxicillin group. Of those enrolled, 22 in the fleroxacin group and 30 (29 for clinical efficacy) in the amoxicillin group were included in the efficacy analysis. All were included in the safety analysis. Clinical success was noted in 21 (95%) of 22 fleroxacin-treated patients and 22 (76%) of 29 amoxicillin-treated patients. Bacteriologic cure was obtained in 21 (95%) of 22 of the fleroxacin group and 18 (60%) of 30 of the amoxicillin group. One Haemophilus parainfluenzae strain persisted with fleroxacin. Persisting organisms with amoxicillin included Haemophilus influenzae (four), Haemophilus parainfluenzae (three), Escherichia coli (two), Streptococcus pneumoniae (one), Neisseria species (one), and Proteus mirabilis (one). Adverse events were reported by 41% of 102 patients receiving fleroxacin and 15% of 92 patients receiving amoxicillin. Insomnia, dizziness, and nausea occurred more frequently with fleroxacin. Fleroxacin may be indicated for the treatment of acute bacterial infection in chronic bronchitis known to be due to Haemophilus species and Moraxella catarrhalis. The 92% incidence of resistance among the S. pneumoniae isolates recovered from all enrolled patients suggests that fleroxacin may not be useful for such infections.

Authors+Show Affiliations

Veterans Administration Outpatient Clinic, Pulmonary Section, Boston, Massachusetts 02114.

Pub Type(s)

Clinical Trial
Comparative Study
Journal Article
Multicenter Study
Randomized Controlled Trial

Language

eng

PubMed ID

8452169

Citation

Chodosh, S. "Efficacy of Fleroxacin Versus Amoxicillin in Acute Exacerbations of Chronic Bronchitis." The American Journal of Medicine, vol. 94, no. 3A, 1993, 131S-135S.
Chodosh S. Efficacy of fleroxacin versus amoxicillin in acute exacerbations of chronic bronchitis. Am J Med. 1993;94(3A):131S-135S.
Chodosh, S. (1993). Efficacy of fleroxacin versus amoxicillin in acute exacerbations of chronic bronchitis. The American Journal of Medicine, 94(3A), 131S-135S.
Chodosh S. Efficacy of Fleroxacin Versus Amoxicillin in Acute Exacerbations of Chronic Bronchitis. Am J Med. 1993 Mar 22;94(3A):131S-135S. PubMed PMID: 8452169.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Efficacy of fleroxacin versus amoxicillin in acute exacerbations of chronic bronchitis. A1 - Chodosh,S, PY - 1993/3/22/pubmed PY - 1993/3/22/medline PY - 1993/3/22/entrez SP - 131S EP - 135S JF - The American journal of medicine JO - Am J Med VL - 94 IS - 3A N2 - In a multicenter study the efficacy and safety of oral fleroxacin at 400 mg once a day and amoxicillin at 500 mg three times daily for 7 days were compared for the treatment of patients with acute bacterial exacerbations of chronic bronchitis due to drug-susceptible bacteria. A total of 194 patients were enrolled, 102 in the fleroxacin group and 92 in the amoxicillin group. Of those enrolled, 22 in the fleroxacin group and 30 (29 for clinical efficacy) in the amoxicillin group were included in the efficacy analysis. All were included in the safety analysis. Clinical success was noted in 21 (95%) of 22 fleroxacin-treated patients and 22 (76%) of 29 amoxicillin-treated patients. Bacteriologic cure was obtained in 21 (95%) of 22 of the fleroxacin group and 18 (60%) of 30 of the amoxicillin group. One Haemophilus parainfluenzae strain persisted with fleroxacin. Persisting organisms with amoxicillin included Haemophilus influenzae (four), Haemophilus parainfluenzae (three), Escherichia coli (two), Streptococcus pneumoniae (one), Neisseria species (one), and Proteus mirabilis (one). Adverse events were reported by 41% of 102 patients receiving fleroxacin and 15% of 92 patients receiving amoxicillin. Insomnia, dizziness, and nausea occurred more frequently with fleroxacin. Fleroxacin may be indicated for the treatment of acute bacterial infection in chronic bronchitis known to be due to Haemophilus species and Moraxella catarrhalis. The 92% incidence of resistance among the S. pneumoniae isolates recovered from all enrolled patients suggests that fleroxacin may not be useful for such infections. SN - 0002-9343 UR - https://www.unboundmedicine.com/medline/citation/8452169/Efficacy_of_fleroxacin_versus_amoxicillin_in_acute_exacerbations_of_chronic_bronchitis_ L2 - https://medlineplus.gov/acutebronchitis.html DB - PRIME DP - Unbound Medicine ER -